Suppr超能文献

诺如病毒 VLPs 和轮状病毒 VP6 蛋白作为联合疫苗用于儿童胃肠炎。

Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis.

机构信息

Vaccine Research Center, University of Tampere Medical School, Tampere, Finland.

出版信息

Vaccine. 2011 Oct 19;29(45):8126-33. doi: 10.1016/j.vaccine.2011.08.026. Epub 2011 Aug 18.

Abstract

Noroviruses (NoVs) and rotaviruses (RVs) are the two most important viral causes of severe gastroenteritis in young children worldwide. Live oral RV vaccines are already part of routine childhood immunization in many countries, but may be associated with low risk of intussusception and other potential risks associated with live vaccines. NoV capsid-derived virus-like particles (VLPs) are in early phase clinical trials, but there is no vaccine available yet. We suggest that there is a need for non-live vaccines against both enteric pathogens. We have combined NoV GII-4 VLPs and human RV recombinant VP6 (rVP6) protein produced by recombinant baculovirus (BV) expression system in insect cells and used this combination vaccine to immunize BALB/c mice parenterally. Strong systemic cross-reactive and cross-blocking antibody responses towards NoV and RV were induced, and there was no interference of the immune response to either antigen given in combination. Rather, we observed an adjuvant effect of rVP6 on the NoV-specific homologous and heterologous immune responses to genotypes not included in a vaccine formulation.

摘要

诺如病毒(NoV)和轮状病毒(RV)是全球导致婴幼儿严重胃肠炎的两个最重要的病毒病原体。口服活 RV 疫苗已在许多国家纳入常规儿童免疫计划,但可能与肠套叠等与活疫苗相关的低风险以及其他潜在风险相关。NoV 衣壳衍生的病毒样颗粒(VLPs)处于早期临床试验阶段,但目前尚无可用疫苗。我们认为,针对这两种肠道病原体都需要非活疫苗。我们将 NoV GII-4 VLP 与通过重组杆状病毒(BV)表达系统在昆虫细胞中产生的人 RV 重组 VP6(rVP6)蛋白结合,并将该联合疫苗用于经肠胃外免疫 BALB/c 小鼠。诱导了针对 NoV 和 RV 的强烈的系统交叉反应性和交叉阻断抗体反应,并且组合使用两种抗原不会干扰对任何一种抗原的免疫反应。相反,我们观察到 rVP6 对未包含在疫苗配方中的基因型的 NoV 特异性同源和异源免疫反应具有佐剂作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验